Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2

Prior treatment

• Participant who has had prior treatment with mezigdomide or carfilzomib.
• Participant who has had any investigational agents within 28 days or 5 half-lives (whichever is shorter) of initiating study intervention.
• Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study intervention.

Other

• Participant with known central nervous system (CNS) involvement with myeloma.

• Participant has documented diagnosis of multiple myeloma (MM) and measurable disease, defined as any of the following: a. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or b. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, c. For participants without measurable disease in sPEP or uPEP: sFLC levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal κ/λ FLC ratio.
• Participant has received at least 1 prior line of anti-myeloma therapy.
• Participant must have received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody. For country-specific requirements, refer to Appendix12.
• Participant achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.
• Participant must have documented disease progression during or after their last anti-myeloma regimen.
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.